Moderna Hopes to Have Covid Vaccine Approved by End of Year

The video discusses Moderna's COVID-19 vaccine, highlighting its 95% efficacy based on a phase three study involving 40,000 participants. It emphasizes the vaccine's potential to prevent severe disease, which could significantly reduce hospitalizations and impact on mental health and the economy. The speaker outlines the steps being taken to submit data to regulatory agencies worldwide, aiming for emergency use approval by the end of the year, with 20 million doses ready for distribution upon approval.

What was the reported efficacy of Moderna's vaccine in the phase three study?

• 99%

• 85%

• 90%

• 95%

How many participants were involved in Moderna's phase three study?

• 50,000

• 20,000

• 30,000

• 40,000

What is the potential impact of the vaccine on severe disease according to the announcement?

• It may increase severe disease cases.

• It may have no effect on severe disease.

• It may only affect mild symptoms.

• It may reduce the chance of severe disease.

What is the expected timeline for finalizing the vaccine data and seeking regulatory approval?

• Within 3 to 5 days

• Within 7 to 15 days

• Within 20 to 30 days

• Within 1 to 2 months

How many doses does Moderna plan to have ready for distribution by the end of the year?

• 20 million

• 15 million

• 10 million

• 25 million